# Prime Medicine, Inc. (PRME) · Edgar & Edgarette company card

> Prime Medicine (PRME) grew revenue 55.3% in FY2025 to $5 million, operating margin -4498% against a -15.8% median for biological products, (no diagnostic substances), equity 35.3% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1894562 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/PRME) · [JSON](https://www.pops4.com/boards/company/PRME.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $5M |
| Revenue growth, 1 year | 55.3% |
| Revenue growth per year | — |
| Operating margin | -4498.1% (prior year -6787.4%) |
| Net margin | -4342.4% |
| Operating cash flow | −$163M |
| Capital spending | $5M |
| Free cash flow | −$167M |
| Cash | $63M |
| Long-term debt | — |
| Total assets | $343M |
| Total equity | $121M |
| Equity ÷ assets | 35.3% |
| Return on equity | -166.4% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -9.21 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -4498.1% in FY2025; revenue is hard to predict: its 80% range is ±28%

## Edgarette's reading

Exposure: revenue $4.6M (FY2025). Experience: revenue up 55.3% on the year; operating margin -4498.1%, up from -6787.4%. Soundness: equity 35.3% of assets, return on equity -166.4%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $5.3M and $9.5M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -4498.1% against a -15.8% median; growth 55.3% against 21.4%.

Range logged 2026-11-13, receipt ee4ef6cf47b1191f, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-04-16 ([filing](https://www.sec.gov/Archives/edgar/data/1894562/000162828026025372/0001628280-26-025372-index.htm))

## Recent filings

- 10-Q · filed 2026-11-12 · [filing](https://www.sec.gov/Archives/edgar/data/1894562/000162828026073392/0001628280-26-073392-index.htm)
- 8-K · filed 2026-11-12 · 2.02 Results of Operations and Financial Condition · [filing](https://www.sec.gov/Archives/edgar/data/1894562/000162828026073372/0001628280-26-073372-index.htm)
- 8-K · filed 2026-11-12 · 1.01 Entry into a Material Definitive Agreement · [filing](https://www.sec.gov/Archives/edgar/data/1894562/000162828026073131/0001628280-26-073131-index.htm)
- 8-K · filed 2026-11-10 · 2.02 Results of Operations and Financial Condition; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1894562/000162828026072713/0001628280-26-072713-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1894562/000162828026053883/0001628280-26-053883-index.htm)
- 8-K · filed 2026-08-06 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1894562/000162828026053878/0001628280-26-053878-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001894562.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1894562

## Cite

POPS4, Edgar & Edgarette: Prime Medicine, Inc. (PRME) company card, from the company's own SEC filings, accessed 2026-11-13, https://www.pops4.com/boards/company/PRME. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.